AustralieFrV1, Main, Exploration, bibRecord, 002625

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

Identifieur interne : 002625 ( Main/Exploration ); précédent : 002624; suivant : 002626

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

Auteurs : David Goldstein [Australie] ; Robert Hassan El-Maraghi ; Pascal Hammel ; Volker Heinemann ; Volker Kunzmann ; Javier Sastre ; Werner Scheithauer ; Salvatore Siena ; Josep Tabernero ; Luis Teixeira ; Giampaolo Tortora ; Jean-Luc Van Laethem ; Rosemary Young ; Darryl Neil Penenberg ; Brian Lu ; Alfredo Romano ; Daniel D. Von Hoff

Source :

Journal of the National Cancer Institute [ 1460-2105 ] ; 2015.

RBID : pubmed:25638248

Descripteurs français

KwdFr :
- Adulte, Adulte d'âge moyen, Adénocarcinome (mortalité), Adénocarcinome (secondaire), Adénocarcinome (traitement médicamenteux), Albumines (administration et posologie), Albumines (effets indésirables), Antigènes glycanniques associés aux tumeurs (sang), Calendrier d'administration des médicaments, Coopération internationale, Désoxycytidine (administration et posologie), Désoxycytidine (analogues et dérivés), Désoxycytidine (effets indésirables), Estimation de Kaplan-Meier, Femelle, Granulocytes neutrophiles (), Humains, Lymphocytes (), Marqueurs biologiques tumoraux (sang), Mâle, Paclitaxel (administration et posologie), Paclitaxel (effets indésirables), Pronostic, Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Résultat thérapeutique, Sujet âgé, Survie sans rechute, Tumeurs du foie (mortalité), Tumeurs du foie (secondaire), Tumeurs du foie (traitement médicamenteux), Tumeurs du pancréas (anatomopathologie), Tumeurs du pancréas (mortalité), Tumeurs du pancréas (traitement médicamenteux), Études de suivi.
MESH :
- administration et posologie : Albumines, Désoxycytidine, Paclitaxel.
- analogues et dérivés : Désoxycytidine.
- anatomopathologie : Tumeurs du pancréas.
- effets indésirables : Albumines, Désoxycytidine, Paclitaxel, Protocoles de polychimiothérapie antinéoplasique.
- mortalité : Adénocarcinome, Tumeurs du foie, Tumeurs du pancréas.
- sang : Antigènes glycanniques associés aux tumeurs, Marqueurs biologiques tumoraux.
- secondaire : Adénocarcinome, Tumeurs du foie.
- traitement médicamenteux : Adénocarcinome, Tumeurs du foie, Tumeurs du pancréas.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Coopération internationale, Estimation de Kaplan-Meier, Femelle, Granulocytes neutrophiles, Humains, Lymphocytes, Mâle, Pronostic, Résultat thérapeutique, Sujet âgé, Survie sans rechute, Études de suivi.

English descriptors

KwdEn :
- Adenocarcinoma (drug therapy), Adenocarcinoma (mortality), Adenocarcinoma (secondary), Adult, Aged, Albumins (administration & dosage), Albumins (adverse effects), Antigens, Tumor-Associated, Carbohydrate (blood), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers, Tumor (blood), Deoxycytidine (administration & dosage), Deoxycytidine (adverse effects), Deoxycytidine (analogs & derivatives), Disease-Free Survival, Drug Administration Schedule, Female, Follow-Up Studies, Humans, International Cooperation, Kaplan-Meier Estimate, Liver Neoplasms (drug therapy), Liver Neoplasms (mortality), Liver Neoplasms (secondary), Lymphocytes (drug effects), Male, Middle Aged, Neutrophils (drug effects), Paclitaxel (administration & dosage), Paclitaxel (adverse effects), Pancreatic Neoplasms (drug therapy), Pancreatic Neoplasms (mortality), Pancreatic Neoplasms (pathology), Prognosis, Treatment Outcome.
MESH :
- chemical , administration & dosage : Albumins, Deoxycytidine, Paclitaxel.
- chemical , adverse effects : Albumins, Deoxycytidine, Paclitaxel.
- chemical , analogs & derivatives : Deoxycytidine.
- chemical , blood : Antigens, Tumor-Associated, Carbohydrate, Biomarkers, Tumor.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- drug effects : Lymphocytes, Neutrophils.
- drug therapy : Adenocarcinoma, Liver Neoplasms, Pancreatic Neoplasms.
- mortality : Adenocarcinoma, Liver Neoplasms, Pancreatic Neoplasms.
- pathology : Pancreatic Neoplasms.
- secondary : Adenocarcinoma, Liver Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Disease-Free Survival, Drug Administration Schedule, Female, Follow-Up Studies, Humans, International Cooperation, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis, Treatment Outcome.

Abstract

Positive findings from the phase III MPACT trial led to the regulatory approval of nab-paclitaxel plus gemcitabine as a treatment option for patients with metastatic pancreatic cancer. This report is an update of overall survival (OS) based on longer follow-up.

DOI: 10.1093/jnci/dju413
PubMed: 25638248

Affiliations:

Australie

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.</title>
<author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name>
<affiliation wicri:level="1"><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH). david.goldstein@sesiahs.health.nsw.gov.au.</nlm:affiliation>
<country wicri:rule="url">Australie</country>
</affiliation>
</author>
<author><name sortKey="El Maraghi, Robert Hassan" sort="El Maraghi, Robert Hassan" uniqKey="El Maraghi R" first="Robert Hassan" last="El-Maraghi">Robert Hassan El-Maraghi</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Hammel, Pascal" sort="Hammel, Pascal" uniqKey="Hammel P" first="Pascal" last="Hammel">Pascal Hammel</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Heinemann, Volker" sort="Heinemann, Volker" uniqKey="Heinemann V" first="Volker" last="Heinemann">Volker Heinemann</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kunzmann, Volker" sort="Kunzmann, Volker" uniqKey="Kunzmann V" first="Volker" last="Kunzmann">Volker Kunzmann</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Sastre, Javier" sort="Sastre, Javier" uniqKey="Sastre J" first="Javier" last="Sastre">Javier Sastre</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Scheithauer, Werner" sort="Scheithauer, Werner" uniqKey="Scheithauer W" first="Werner" last="Scheithauer">Werner Scheithauer</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Siena, Salvatore" sort="Siena, Salvatore" uniqKey="Siena S" first="Salvatore" last="Siena">Salvatore Siena</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Teixeira, Luis" sort="Teixeira, Luis" uniqKey="Teixeira L" first="Luis" last="Teixeira">Luis Teixeira</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tortora, Giampaolo" sort="Tortora, Giampaolo" uniqKey="Tortora G" first="Giampaolo" last="Tortora">Giampaolo Tortora</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Van Laethem, Jean Luc" sort="Van Laethem, Jean Luc" uniqKey="Van Laethem J" first="Jean-Luc" last="Van Laethem">Jean-Luc Van Laethem</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Young, Rosemary" sort="Young, Rosemary" uniqKey="Young R" first="Rosemary" last="Young">Rosemary Young</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Penenberg, Darryl Neil" sort="Penenberg, Darryl Neil" uniqKey="Penenberg D" first="Darryl Neil" last="Penenberg">Darryl Neil Penenberg</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lu, Brian" sort="Lu, Brian" uniqKey="Lu B" first="Brian" last="Lu">Brian Lu</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Romano, Alfredo" sort="Romano, Alfredo" uniqKey="Romano A" first="Alfredo" last="Romano">Alfredo Romano</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Von Hoff, Daniel D" sort="Von Hoff, Daniel D" uniqKey="Von Hoff D" first="Daniel D" last="Von Hoff">Daniel D. Von Hoff</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25638248</idno>
<idno type="pmid">25638248</idno>
<idno type="doi">10.1093/jnci/dju413</idno>
<idno type="wicri:Area/PubMed/Corpus">003111</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003111</idno>
<idno type="wicri:Area/PubMed/Curation">003015</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003015</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003015</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003015</idno>
<idno type="wicri:Area/Ncbi/Merge">002212</idno>
<idno type="wicri:Area/Ncbi/Curation">002212</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002212</idno>
<idno type="wicri:Area/Main/Merge">002624</idno>
<idno type="wicri:Area/Main/Curation">002625</idno>
<idno type="wicri:Area/Main/Exploration">002625</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.</title>
<author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name>
<affiliation wicri:level="1"><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH). david.goldstein@sesiahs.health.nsw.gov.au.</nlm:affiliation>
<country wicri:rule="url">Australie</country>
</affiliation>
</author>
<author><name sortKey="El Maraghi, Robert Hassan" sort="El Maraghi, Robert Hassan" uniqKey="El Maraghi R" first="Robert Hassan" last="El-Maraghi">Robert Hassan El-Maraghi</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Hammel, Pascal" sort="Hammel, Pascal" uniqKey="Hammel P" first="Pascal" last="Hammel">Pascal Hammel</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Heinemann, Volker" sort="Heinemann, Volker" uniqKey="Heinemann V" first="Volker" last="Heinemann">Volker Heinemann</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kunzmann, Volker" sort="Kunzmann, Volker" uniqKey="Kunzmann V" first="Volker" last="Kunzmann">Volker Kunzmann</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Sastre, Javier" sort="Sastre, Javier" uniqKey="Sastre J" first="Javier" last="Sastre">Javier Sastre</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Scheithauer, Werner" sort="Scheithauer, Werner" uniqKey="Scheithauer W" first="Werner" last="Scheithauer">Werner Scheithauer</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Siena, Salvatore" sort="Siena, Salvatore" uniqKey="Siena S" first="Salvatore" last="Siena">Salvatore Siena</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Teixeira, Luis" sort="Teixeira, Luis" uniqKey="Teixeira L" first="Luis" last="Teixeira">Luis Teixeira</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tortora, Giampaolo" sort="Tortora, Giampaolo" uniqKey="Tortora G" first="Giampaolo" last="Tortora">Giampaolo Tortora</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Van Laethem, Jean Luc" sort="Van Laethem, Jean Luc" uniqKey="Van Laethem J" first="Jean-Luc" last="Van Laethem">Jean-Luc Van Laethem</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Young, Rosemary" sort="Young, Rosemary" uniqKey="Young R" first="Rosemary" last="Young">Rosemary Young</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Penenberg, Darryl Neil" sort="Penenberg, Darryl Neil" uniqKey="Penenberg D" first="Darryl Neil" last="Penenberg">Darryl Neil Penenberg</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lu, Brian" sort="Lu, Brian" uniqKey="Lu B" first="Brian" last="Lu">Brian Lu</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Romano, Alfredo" sort="Romano, Alfredo" uniqKey="Romano A" first="Alfredo" last="Romano">Alfredo Romano</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Von Hoff, Daniel D" sort="Von Hoff, Daniel D" uniqKey="Von Hoff D" first="Daniel D" last="Von Hoff">Daniel D. Von Hoff</name>
<affiliation><nlm:affiliation>Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).</nlm:affiliation>
<wicri:noCountry code="subField">AZ (DDVH)</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of the National Cancer Institute</title>
<idno type="eISSN">1460-2105</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (drug therapy)</term>
<term>Adenocarcinoma (mortality)</term>
<term>Adenocarcinoma (secondary)</term>
<term>Adult</term>
<term>Aged</term>
<term>Albumins (administration & dosage)</term>
<term>Albumins (adverse effects)</term>
<term>Antigens, Tumor-Associated, Carbohydrate (blood)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Biomarkers, Tumor (blood)</term>
<term>Deoxycytidine (administration & dosage)</term>
<term>Deoxycytidine (adverse effects)</term>
<term>Deoxycytidine (analogs & derivatives)</term>
<term>Disease-Free Survival</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>International Cooperation</term>
<term>Kaplan-Meier Estimate</term>
<term>Liver Neoplasms (drug therapy)</term>
<term>Liver Neoplasms (mortality)</term>
<term>Liver Neoplasms (secondary)</term>
<term>Lymphocytes (drug effects)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neutrophils (drug effects)</term>
<term>Paclitaxel (administration & dosage)</term>
<term>Paclitaxel (adverse effects)</term>
<term>Pancreatic Neoplasms (drug therapy)</term>
<term>Pancreatic Neoplasms (mortality)</term>
<term>Pancreatic Neoplasms (pathology)</term>
<term>Prognosis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Adénocarcinome (mortalité)</term>
<term>Adénocarcinome (secondaire)</term>
<term>Adénocarcinome (traitement médicamenteux)</term>
<term>Albumines (administration et posologie)</term>
<term>Albumines (effets indésirables)</term>
<term>Antigènes glycanniques associés aux tumeurs (sang)</term>
<term>Calendrier d'administration des médicaments</term>
<term>Coopération internationale</term>
<term>Désoxycytidine (administration et posologie)</term>
<term>Désoxycytidine (analogues et dérivés)</term>
<term>Désoxycytidine (effets indésirables)</term>
<term>Estimation de Kaplan-Meier</term>
<term>Femelle</term>
<term>Granulocytes neutrophiles ()</term>
<term>Humains</term>
<term>Lymphocytes ()</term>
<term>Marqueurs biologiques tumoraux (sang)</term>
<term>Mâle</term>
<term>Paclitaxel (administration et posologie)</term>
<term>Paclitaxel (effets indésirables)</term>
<term>Pronostic</term>
<term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Survie sans rechute</term>
<term>Tumeurs du foie (mortalité)</term>
<term>Tumeurs du foie (secondaire)</term>
<term>Tumeurs du foie (traitement médicamenteux)</term>
<term>Tumeurs du pancréas (anatomopathologie)</term>
<term>Tumeurs du pancréas (mortalité)</term>
<term>Tumeurs du pancréas (traitement médicamenteux)</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albumins</term>
<term>Deoxycytidine</term>
<term>Paclitaxel</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albumins</term>
<term>Deoxycytidine</term>
<term>Paclitaxel</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Deoxycytidine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antigens, Tumor-Associated, Carbohydrate</term>
<term>Biomarkers, Tumor</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albumines</term>
<term>Désoxycytidine</term>
<term>Paclitaxel</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Désoxycytidine</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du pancréas</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lymphocytes</term>
<term>Neutrophils</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term>
<term>Liver Neoplasms</term>
<term>Pancreatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albumines</term>
<term>Désoxycytidine</term>
<term>Paclitaxel</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Adenocarcinoma</term>
<term>Liver Neoplasms</term>
<term>Pancreatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Adénocarcinome</term>
<term>Tumeurs du foie</term>
<term>Tumeurs du pancréas</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Pancreatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antigènes glycanniques associés aux tumeurs</term>
<term>Marqueurs biologiques tumoraux</term>
</keywords>
<keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Adénocarcinome</term>
<term>Tumeurs du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Adenocarcinoma</term>
<term>Liver Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome</term>
<term>Tumeurs du foie</term>
<term>Tumeurs du pancréas</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Disease-Free Survival</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>International Cooperation</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prognosis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Calendrier d'administration des médicaments</term>
<term>Coopération internationale</term>
<term>Estimation de Kaplan-Meier</term>
<term>Femelle</term>
<term>Granulocytes neutrophiles</term>
<term>Humains</term>
<term>Lymphocytes</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Survie sans rechute</term>
<term>Études de suivi</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Positive findings from the phase III MPACT trial led to the regulatory approval of nab-paclitaxel plus gemcitabine as a treatment option for patients with metastatic pancreatic cancer. This report is an update of overall survival (OS) based on longer follow-up.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
</country>
</list>
<tree><noCountry><name sortKey="El Maraghi, Robert Hassan" sort="El Maraghi, Robert Hassan" uniqKey="El Maraghi R" first="Robert Hassan" last="El-Maraghi">Robert Hassan El-Maraghi</name>
<name sortKey="Hammel, Pascal" sort="Hammel, Pascal" uniqKey="Hammel P" first="Pascal" last="Hammel">Pascal Hammel</name>
<name sortKey="Heinemann, Volker" sort="Heinemann, Volker" uniqKey="Heinemann V" first="Volker" last="Heinemann">Volker Heinemann</name>
<name sortKey="Kunzmann, Volker" sort="Kunzmann, Volker" uniqKey="Kunzmann V" first="Volker" last="Kunzmann">Volker Kunzmann</name>
<name sortKey="Lu, Brian" sort="Lu, Brian" uniqKey="Lu B" first="Brian" last="Lu">Brian Lu</name>
<name sortKey="Penenberg, Darryl Neil" sort="Penenberg, Darryl Neil" uniqKey="Penenberg D" first="Darryl Neil" last="Penenberg">Darryl Neil Penenberg</name>
<name sortKey="Romano, Alfredo" sort="Romano, Alfredo" uniqKey="Romano A" first="Alfredo" last="Romano">Alfredo Romano</name>
<name sortKey="Sastre, Javier" sort="Sastre, Javier" uniqKey="Sastre J" first="Javier" last="Sastre">Javier Sastre</name>
<name sortKey="Scheithauer, Werner" sort="Scheithauer, Werner" uniqKey="Scheithauer W" first="Werner" last="Scheithauer">Werner Scheithauer</name>
<name sortKey="Siena, Salvatore" sort="Siena, Salvatore" uniqKey="Siena S" first="Salvatore" last="Siena">Salvatore Siena</name>
<name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name>
<name sortKey="Teixeira, Luis" sort="Teixeira, Luis" uniqKey="Teixeira L" first="Luis" last="Teixeira">Luis Teixeira</name>
<name sortKey="Tortora, Giampaolo" sort="Tortora, Giampaolo" uniqKey="Tortora G" first="Giampaolo" last="Tortora">Giampaolo Tortora</name>
<name sortKey="Van Laethem, Jean Luc" sort="Van Laethem, Jean Luc" uniqKey="Van Laethem J" first="Jean-Luc" last="Van Laethem">Jean-Luc Van Laethem</name>
<name sortKey="Von Hoff, Daniel D" sort="Von Hoff, Daniel D" uniqKey="Von Hoff D" first="Daniel D" last="Von Hoff">Daniel D. Von Hoff</name>
<name sortKey="Young, Rosemary" sort="Young, Rosemary" uniqKey="Young R" first="Rosemary" last="Young">Rosemary Young</name>
</noCountry>
<country name="Australie"><noRegion><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002625 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002625 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25638248
   |texte=   nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25638248" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.